Drug Trial Radar · NCT06834282
CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)
Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
18
Planned (sponsor's estimate)
Start
Apr 7, 2025
Primary completion
Dec 31, 2026
Study completion Dec 31, 2029
Sponsor
- Lead sponsor
- CERo Therapeutics Holdings, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 19, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a first in human, multi center, open label, phase 1/1b study to evaluate the safety and preliminary efficacy of CER-1236 in patients with relapsed/refractory (R/R), measurable residual disease (MRD) positive acute myeloid leukemia (AML), or TP53mut disease.
Conditions
- AML
- Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
Interventions
CER-1236Drug
an autologous chimeric engulfment receptor T-cell
CyclophosphamideDrug
Lymphodepleting chemotherapy
FludarabineDrug
Lymphodepleting chemotherapy
MesnaDrug
Chemoprotectant
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events (AEs) and serious adverse events (SAEs) - (Part 1)Time frame: 2 year
- Incidence of dose-limiting toxicities (DLTs) of CER-1236 Monotherapy - (Part 1)Time frame: 28 days
- Estimation of the objective response rate (ORR), complete response (CR), composite complete response (cCR), and measurable residual disease (MRD) negativity rates - (Part 2)Time frame: 2 years
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
University of California, Davis Comprehensive Cancer Center
Sacramento, California · Recruiting
Colorado Blood Cancer Institute
Denver, Colorado · Recruiting
Sarah Cannon Research Insitute
Nashville, Tennessee · Recruiting
The University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
Fred Hutchinson Cancer Center
Seattle, Washington · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.